Classes
DEA Class; Rx
Common Brand Names; Nafcil, Nallpen
- Penicillins, Penicillinase-Resistant
Description
Oral semisynthetic isoxazolyl antistaphylococcal penicillin. Most active of the isoxazolyl antistaphylococcal penicillins. Stable against penicillinase and active against many of the penicillinase-producing strains of Staphylococcus aureus. Clinical uses include skin and soft-tissue, bone and joint, respiratory tract, and urinary tract infections.
Indications
Indicated for the treatment of mastitis.
Contraindications
A history of a hypersensitivity (anaphylactic) reaction to any penicillin
Solutions containing dextrose in patients with known allergy to corn or corn products
Adverse Effects
- Hypersensitivity
- Neutropenia
- Interstitial nephritis
- Possible hypokalemia
- Neurotoxicity (high doses)
- Pseudomembranous colitis
- Phlebitis (oxacillin preferred in peds)
Warnings
Evaluate renal, hepatic, hematologic systems periodically during prolonged treatment
Serious and occasionally fatal hypersensitivity (anaphylactic) reactions reported; reactions are more likely to occur in individuals with history of penicillin hypersensitivity and/or a history of sensitivity to multiple allergens; inquire about previous hypersensitivity reactions to penicillins, cephalosporins, or other allergens before initiating therapy; if allergic reaction occurs, discontinue treatment and institute appropriate therapy
Use with caution in patients with histories of significant allergies and/or asthma; whenever allergic reactions occur, withdraw penicillin unless, in the opinion of the physician, the condition being treated is life-threatening and amenable only to penicillin therapy
Liver/biliary tract is primary route of nafcillin clearance; exercise caution when patients with concomitant hepatic insufficiency and renal dysfunction are treated with this drug
Prescribing the antibiotic in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to patient and increases risk of development of drug-resistant bacteria
The use of antibiotics may result in overgrowth of nonsusceptible organisms; if new infections due to bacteria or fungi occur, discontinue drug and take appropriate measures
To optimize therapy, determine causative organisms and susceptibility; > 10 d treatment to eliminate infection and prevent sequelae (eg, endocarditis, rheumatic fever); take cultures after treatment to confirm that infection is eradicated
Elevation of liver transaminases and/or cholestasis may occur, specifically with administration of high doses
Urinalysis, serum blood urea nitrogen, and creatinine determinations should be performed at baseline and periodically during therapy; serum bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, and gamma-glutamyl transferase should be obtained at baseline and periodically during therapy, especially when using high nafcillin doses; in patients with worsening hepatic
Renal tubular damage and interstitial nephritis associated with administration of nafcillin; manifestations of nephrotoxicity are hematuria, proteinuria, and acute kidney injury, and may be associated with rash, fever, and eosinophilia; majority of cases resolve upon discontinuation of nafcillin; some patients, may require dialysis treatment and may develop permanent renal damage
Pregnancy and Lactation
Pregnancy Category: B
Lactation: Excreted into breast milk; use caution
Maximum Dosage
1 g/day PO per FDA-approved labeling; however, doses up to 2 g/day PO have been used off-label.
1 g/day PO per FDA-approved labeling; however, doses up to 2 g/day PO have been used off-label.
25 mg/kg/day PO (Max: 1 g/day) per FDA-approved labeling; however, doses up to 50 mg/kg/day PO (Max: 2 g/day) have been used off-label.
25 mg/kg/day PO (Max: 1 g/day) per FDA-approved labeling; however, doses up to 50 mg/kg/day PO (Max: 2 g/day) have been used off-label.
How supplied
Nafcillin
injectable solution
- 20mg/mL
- 2g/100mL
powder for injection
- 1g
- 2g
- 10g